Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ZBH files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsZimmer Biomet increases 2026 share buyback plan to up to $1.0 billion
Filed May 12, 2026 · Period ending May 12, 2026 · ~1 min read
Key Changes
-
high
Company will repurchase up to $1.0 billion of shares during fiscal 2026, an increase from previously disclosed capital allocation plans. The buyback operates under a $1.5 billion authorization approved by the Board in February 2026.
Item 8.01 view on EDGAR → -
high
The increased repurchase commitment signals management confidence in the business and represents a more aggressive return of capital to shareholders than originally planned for the year.
Item 8.01 view on EDGAR → -
low
Press release furnished under Item 7.01 is not deemed filed under the Exchange Act and will not be incorporated by reference into other SEC filings unless expressly stated.
Item 7.01 verify on EDGAR →
Summary
Zimmer Biomet announced it will repurchase up to $1.0 billion of its shares during fiscal year 2026, a significant increase from its previously disclosed capital allocation plans. The buyback operates under a $1.5 billion authorization that the Board approved in February 2026.
This more aggressive share repurchase program suggests management believes the stock is undervalued and represents a strong vote of confidence in the company's financial position and future prospects. For retail investors, this is positive news. Share buybacks reduce the number of outstanding shares, which can boost earnings per share and potentially support the stock price.
The fact that management is increasing the buyback beyond original plans indicates they see this as an attractive use of capital compared to other alternatives like acquisitions or debt reduction. Watch for quarterly updates on the actual pace of repurchases and whether the company completes the full up to $1.0 billion program during 2026. Also monitor if this increased capital return affects the company's ability to invest in growth initiatives or maintain its dividend.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 7.01 by reference.
The company furnished a press release as Exhibit 99.1 under Item 7.01. The 8-K references Item 5.02 but does not provide details about the content of that item or the press release. The filing explicitly states this information is being furnished rather than filed, meaning it is not subject to Section 18 liabilities of the Exchange Act and will not be incorporated by reference into other filings unless expressly stated. Note: these figures were previously disclosed in the company's Apr 28, 2026 8-K.
Event · Item 9.01 — Financial Statements and Exhibits
Zimmer Biomet filed an 8-K attaching a press release dated May 12, 2026; no material business event disclosed in the filing body.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Press release dated May 12, 2026
The 8-K references an attached press release dated May 12, 2026 (Exhibit 99.1). The filing body itself contains no substantive disclosure about the press release content, making this a procedural filing. The actual material information would be in the press release exhibit, which is not included in the provided text.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 1, 2026 · How we verify